Semaglutide Shows 20% Reduction in Major Cardiovascular Events: SELECT Trial Results
The landmark SELECT trial demonstrates that semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease, independent of weight loss effects. This groundbreaking finding suggests direct cardioprotective mechanisms beyond metabolic improvements.
Read Full Analysis →